Rivermark Medical is developing the FloStent™ System, a minimally-invasive device for treating Benign Prostatic Hyperplasia (BPH) that is implanted using a standard cystoscope during an outpatient visit. This technology provides rapid relief from urinary symptoms with minimal downtime, allowing patients to quickly return to their daily activities.
Funding
$34.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Benign Prostatic Hyperplasia (BPH) causes urinary symptoms that negatively impact quality of life. Current treatments often require invasive procedures, extended recovery times, and may not provide immediate relief.
Solution
Rivermark Medical's FloStent™ System offers a minimally-invasive solution for BPH, providing rapid relief from urinary symptoms. The FloStent™ is implanted using a standard cystoscope during an outpatient visit, eliminating the need for additional equipment or complex surgical procedures. This approach allows for a quick return to daily activities with minimal downtime and no need for a post-procedural catheter. The device is designed for long-term use but can be easily removed using the same cystoscope if needed, preserving future treatment options.
Target Audience
The primary target audience includes urologists seeking a cost-effective, first-line treatment option for BPH, as well as patients experiencing urinary symptoms due to BPH.
Features
- Minimally invasive implantation via standard cystoscopy
- Rapid relief from BPH symptoms
- Outpatient procedure performed in minutes
- No post-procedural catheter required
- Rapid recovery with minimal downtime
- Reversible with easy removal using a cystoscope
- Designed for long-term use